Clinical Efficacy of Dapagliflozin in Patients wth Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction Associated with Coronary Artery Disease
International Journal of Health Sciences (IJHS) · 2023
DOI: 10.15640/ijhs.v11n2a16 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Health Sciences (IJHS), 2023. Verfasst von Chonghuai Gu und 6 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
Objective
To study the clinical efficacy of Dapagliflozin in patients with coronary heart disease (CHD) combined with Heart Failure with Reduced Ejection Fraction (HFrEF) and type 2 diabetes mellitus (T2DM).
Methods
A retrospective analysis of 202 patients with CHD and T2DM who were hospitalized in our department of cardiovascular medicine and/or underwent PCI treatment from November 2019 to November 2022 was conducted. Patients were divided into two groups according to whether they received Dapagliflozin treatment: the Dapagliflozin group (n=100) and the control group (n=102). A subgroup analysis was performed on the 80 HFrEF patients in the total population, which was also divided into two groups: the Dapagliflozin group (n=44) and the control group (n=36). The incidence of major adverse cardiovascular events (MACE) during hospitalization and the median follow-up period (224.5 days) was recorded and analyzed in both the total population and the subgroup. ResultsThe results of the analysis of the total patient population showed no statistical differences between the two groups in baseline data and related clinical treatment conditions (P>0.05). The follow-up period events analysis showed that the overall MACE event rate in the Dapagliflozin group was lower than that in the control group (6.00% vs. 17.65%), but not statistically significant (P=0.071). The COX regression analysis of MACE events showed that the use of Dapagliflozin was an independent protective factor for MACE events [HR=0.166, 95% CI (0.026-0.953), P=0.047]. In the HFrEF subgroup analysis, there was no significant difference between the two groups in the baseline data analysis (P>0.05). The COX regression analysis in the subgroup analysis showed that the use of Dapagliflozin was a strong protective factor for the HFrEF subgroup during the follow-up period [HR=0.250, 95% CI (0.017-0.518), P
Zitieren
APA
Gu, C., Xiang, X., Zheng, Y., Sun, A., Chen, J., Qiao, R., & Zhao, X. (2023). Clinical Efficacy of Dapagliflozin in Patients wth Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction Associated with Coronary Artery Disease. International Journal of Health Sciences (IJHS). https://doi.org/10.15640/ijhs.v11n2a16
Vancouver
Gu C, Xiang X, Zheng Y, Sun A, Chen J, Qiao R, et al. Clinical Efficacy of Dapagliflozin in Patients wth Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction Associated with Coronary Artery Disease. International Journal of Health Sciences (IJHS). 2023. doi:10.15640/ijhs.v11n2a16
BibTeX
@article{Gu2023,
author = {Gu, Chonghuai and Xiang, Xuejun and Zheng, Yuanxi and Sun, Aijiao and Chen, Jing and Qiao, Rui and Zhao, Xin},
title = {Clinical Efficacy of Dapagliflozin in Patients wth Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction Associated with Coronary Artery Disease},
journal = {International Journal of Health Sciences (IJHS)},
year = {2023},
doi = {10.15640/ijhs.v11n2a16}
}
EUVIMED